Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | Biomarker | disease | BEFREE | Predictors of positive <sup>18</sup>F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. | 29903537 | 2019 | ||||
|
0.060 | Biomarker | disease | BEFREE | We also discuss the sensitivity of FDG-PET imaging in differentiating polymyalgia rheumatica from other diseases that have similar clinical presentation. | 30322478 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | The incidence of significant <sup>18</sup>F-FDG uptake in the definitive PMR group was 6% for wrists and for elbows, 88% for glenohumeral and sternoclavicular joints, 25% for acromioclavicular joints, 81% for spinous processes, 69% for ischial tuberosities, and 81% for greater trochanters. | 29948622 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | It is possible to observe a decrease or even a disappearance of <sup>18</sup>F-FDG uptake after effective therapy, an event which may be useful for the monitoring of treatment as well as for detection of PMR relapse. | 28508663 | 2017 | ||||
|
0.060 | Biomarker | disease | BEFREE | The 4 separate studies in the current protocol focus on: the association of clinical picture of PMR/GCA with PET findings; the validity of 18F-FDG PET/CT scan for diagnosis of PMR/GCA compared with temporal artery biopsy; the prevalence of newly diagnosed malignancies in patients with PMR/GCA, or PMR-like syndrome, with the focus on diagnostic accuracy of 18F-FDG PET/CT scan compared with conventional workup (ie, chest X-ray/abdominal ultrasound); and the impact of disease process, and also steroid treatment on bone mineral density, body composition, and vasculitis/vascular stiffness in PMR/GCA patients. | 28658131 | 2017 | ||||
|
0.060 | Biomarker | disease | BEFREE | Increased praepubic <sup>18</sup>F-FDG uptake in patients with PMR is relatively common and this region should be systematically evaluated during differential diagnosis of rheumatic and malignant disease. | 28265227 | 2017 |